Format

Send to

Choose Destination
J Gastrointestin Liver Dis. 2017 Mar;26(1):59-67. doi: 10.15403/jgld.2014.1121.261.ely.

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis.

Author information

1
Faculty of Medicine, Al Azhar University, Cairo, Egypt. Ahmedelgebaly94@azhar.edu.eg.
2
Ain Shams University, Faculty of Medicine, Cairo University, Cairo, Egypt.
3
Kasr-AlAiny Medical School, Cairo University, Cairo, Egypt.
4
Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
5
Genetic Engineering & Biotechnology Research Institute, University of Sadat City, Egypt.
6
Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt.
7
Faculty of Medicine, Al Azhar University, Cairo, Egypt.
8
Faculty of Medicine, Beni Suef University,Beni Suef, Egypt.
9
Department of Pharmaceutics and Pharmaceutical Sciences, Faculty of Pharmacy, Alexandria University, Egypt.

Abstract

BACKGROUND:

Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.

METHODS:

A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.

RESULTS:

Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.

CONCLUSION:

Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.

PMID:
28338115
DOI:
10.15403/jgld.2014.1121.261.ely
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Iuliu Hatieganu Medical Publishing House
Loading ...
Support Center